指南与共识前列腺癌

前列腺癌挽救治疗:AUA/ASTRO/SUO指南第二部分:根治性前列腺切除术后非转移性生化复发的治疗实施

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
指南 / 共识 · J Urol · 2024-02-29

该指南由AUA、ASTRO和SUO联合制定,基于系统检索(Ovid MEDLINE至2022年7月21日,Cochrane至2022年8月,更新检索至2023年7月26日),针对根治性前列腺切除术后非转移性生化复发患者的挽救治疗实施提出循证与共识推荐。指南强调优化和个体化挽救治疗仍需多学科协作。

要点

  • 指南涵盖根治性前列腺切除术后非转移性生化复发的挽救治疗实施推荐。
  • 推荐基于系统综述与共识制定,检索截至2023年7月26日。
  • 优化和个体化挽救治疗仍需协调的多学科努力。

核心结论

  • 优化和个体化挽救治疗仍是泌尿生殖肿瘤学持续的工作领域,需要良好协调的多学科努力。

研究设计与样本

  • AUA、ASTRO和SUO联合制定的循证与共识指南,基于Ovid MEDLINE(1946年至2022年7月21日)、Cochrane对照试验中心注册库(至2022年8月)和Cochrane系统综述数据库(至2022年8月)的系统检索,更新检索于2023年7月26日进行,并补充审查相关文章的电子数据库参考文献列表。

关键数值与推荐

  • 指南专家组制定了循证与共识的指南声明,为初始根治性局部治疗后出现生化复发的临床局限性疾病患者提供照护指导。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part II of a three-part series focusing on treatment delivery for non-metastatic biochemical recurrence (BCR) after primary radical prostatectomy (RP). Please refer to Part I for discussion of treatment decision-making and Part III for discussion of evaluation and management of recurrence after radiotherapy (RT) and focal therapy, regional recurrence, and oligometastasis. MATERIALS AND METHODS: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE (1946 to July 21, 2022), Cochrane Central Register of Controlled Trials (through August 2022), and Cochrane Database of Systematic Reviews (through August 2022). Update searches were conducted on July 26, 2023. Searches were supplemented by reviewing electronic database reference lists of relevant articles. RESULTS: In a collaborative effort between AUA, ASTRO, and SUO, the Salvage Therapy for Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance for the care of patients who experience BCR after initial definitive local therapy for clinically localized disease. CONCLUSIONS: Optimizing and personalizing the approach to salvage therapy remains an ongoing area of work in the field of genitourinary oncology and represents an area of research and clinical care that requires well-coordinated, multi-disciplinary efforts.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024. PMID: 38421243. doi:10.1097/JU.0000000000003891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。